Amita Goel

Amita founded Celltheon in 2012 after working in Pharma for >25 years at companies like Elan Pharmaceuticals, where she oversaw the development of Tysabri from early R&D through clinical trials. Amita also worked at a start-up company called Arresto Biosciences where she oversaw and managed cell line and process development through various CROs and CMOs. After successfully initiating clinical trials, Arresto was acquired by Gilead and Amita continued to oversee the development of Gilead's first biologics. Having experienced pain points with existing expression platforms (i.e: cell clumping, low expression, instability, long timelines, etc.), Amita set out to improve the industry-standard technology with the goal of preventing therapeutics from falling into the "Valley of Death". Thus, Amita founded Celltheon and developed the Celltheon SMART™ Expression Platform which has enabled the development of 60+ therapeutic proteins since its inception in 2012. Amita has assembled a strong team of advisers and scientific staff that share Amita's vision for the future of biologics manufacturing.